Allogeneic cardiac stem cell administration for acute myocardial infarction

Expert Review of Cardiovascular Therapy

Volumn 13, Issue 3, 2015, Pages 285-299

  Crisostomo, Veronica ^a   Casado, Javier G ^a   Baez Diaz, Claudia ^a   Blazquez, Rebeca ^a   Sanchez Margallo, Francisco M ^a  

^a JESÚS USÓN MINIMALLY INVASIVE SURGERY CENTRE   (Spain)

Author keywords

allogeneic; animal models; cardiac stem cells; experimental therapy; myocardial infarction; myocardial regeneration

Indexed keywords

ATAXIN 1; ISL1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ALLOGENEIC STEM CELL TRANSPLANTATION; CARDIAC STEM CELL; CARDIOSPHERE DERIVED CELL; CELLS BY BODY ANATOMY; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; HEART MUSCLE CELL; HUMAN; IMMUNOGENICITY; NONHUMAN; ONCOGENE C KIT; REVIEW; SAFETY; SIDE POPULATION CELL; ADVERSE EFFECTS; ALLOTRANSPLANTATION; ANIMAL; CYTOLOGY; MYOCARDIAL INFARCTION; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; STEM CELL TRANSPLANTATION; TIME;

ANIMALS; HUMANS; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84923288934     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2015.1011621     Document Type: Review

References (110)

1. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur Heart J 2013;34:3028-34
2. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics- 2014 update: a report from the american heart association. Circulation 2014;129: e28-e292
3. Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myocardial infarction. Arterioscler Thromb Vasc Biol 2008;28: 208-16
4. van der Spoel TIG, Jansen of Lorkeers SJ, Agostoni P, et al. Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc Res 2011;91:649-58
5. Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 2013;113:810-34
6. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the poseidon randomized trial. J Am Med Assoc 2012;308:2369-79
7. Schuleri KH, Feigenbaum GS, Centola M, et al. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur Heart J 2009;30:2722-32
8. Koudstaal S, Jansen of Lorkeers SJ, Gaetani R, et al. Concise review: heart regeneration and the role of cardiac stem cells. Stem Cells Trans Med 2013;2:434-43
9. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008;103: 1204-19
10. Ellison GM, Torella D, Dellegrottaglie S, et al. Endogenous cardiac stem cell activation by insulin-like growth factor-1/hepatocyte growth factor intracoronary injection fosters survival and regeneration of the infarcted pig heart. J Am Coll Cardiol 2011;58:977-86
11. Johnston PV, Sasano T, Mills K, et al. Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation 2009;120:1075-83
12. Malliaras K, Smith RR, Kanazawa H, et al. Validation of contrast-enhanced magnetic resonance imaging to monitor regenerative efficacy after cell therapy in a porcine model of convalescent myocardial infarction. Circulation 2013;128:2764-75
13. Malliaras K, Li TS, Luthringer D, et al. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation 2012;125:100-12
14. Welt FGP, Gallegos R, Connell J, et al. Effect of cardiac stem cells on left-ventricular remodeling in a canine model of chronic myocardial infarction. Circ Heart Fail 2013;6:99-106
15. Li R-K, Mickle DAG, Weisel RD, et al. Optimal time for cardiomyocyte transplantation to maximize myocardial function after left ventricular injury. Ann Thorac Surg 2001;72:1957-63
16. Bolli R, Tang X-L, Sanganalmath SK, et al. Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy. Circulation 2013;128: 122-31
17. Tseliou E, Pollan S, Malliaras K, et al. Allogeneic cardiospheres safely boost cardiac function and attenuate adverse remodeling after myocardial infarction in immunologically mismatched rat strains. J Am Coll Cardiol 2013;61:1108-19
18. Dawn B, Stein AB, Urbanek K, et al. Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. Proc Natl Acad Sci USA 2005;102:3766-71
19. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011;378:1847-57
20. Chugh AR, Beache GM, Loughran JH, et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO Trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation 2012;126:S54-64
21. Cardiac stem cell infusion in patients with ischemic cardiomyopathy (SCIPIO). Available from: https://clinicaltrials.gov/ct2/show/NCT00474461
22. Malliaras K, Makkar RR, Smith RR, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence for therapeutic regeneration in the final 1-year results of the CADUCEUS trial. J Am Coll Cardiol 2014;63:110-22 The final results obtained 1 year after autologous CDC administration in the CADUCEUS trial.
23. Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 2012;379: 895-904
24. CArdiosphere-Derived aUtologous Stem CElls to Reverse ventricUlar dySfunction (CADUCEUS). Available from: https://clinicaltrials.gov/ct2/show/NCT00893360
25. Dimmeler S, Leri A. Aging and disease as modifiers of efficacy of cell therapy. Circ Res 2008;102:1319-30
26. Cheng K, Malliaras K, Smith RR, et al. Human cardiosphere-derived cells from advanced heart failure patients exhibit augmented functional potency in myocardial repair. JACC Heart Fail 2014;2:49-61
27. Kanazawa H, Malliaras K, Yee K, et al. Cardioprotective effect of allogeneic cardiosphere-derived cells: reduction of infarct size and attenuation of no-reflow when administered in the infarct-related artery after reperfusion in pigs with acute myocardial infarction. J Am Coll Cardiol 2013;61(10-S):doi:10.1016/S0735-1097(13)61818-5
28. Baez-Diaz C, Crisostomo V, Maestre J, et al. Safety and efficacy assesment of intracoronary delivery of porcine cardiac stem cells in a swine model of acute myocardial infarction. comparison of two different cell doses. J Am Coll Cardiol 2014;63(12-S):doi: 10.1016/S0735-1097(14)61763-0
29. Crisostomo V, Baez-Diaz C, Maestre J, et al. Allogeneic cardiac stem cell administration for acute myocardial infarction. a timing experimental study in swine. J Am Coll Cardiol 2014; 63(12-S):doi: 10.1016/S0735-1097(14) 61756-3
30. Kanazawa H, Malliaras K, Yee K, et al. Allogeneic cardiosphere-derived cells after reperfusion are effective in reducing infarct size and attenuatting adverse remodelling in pigs with acute myocardial infarction. J Am Coll Cardiol 2013;61(10-S):doi:10.1016/S0735-1097(13)61833-1
31. Yee K, Malliaras K, Kanazawa H, et al. Allogeneic cardiospheres delivered via percutaneous transendocardial injection increase viable myocardium, decrease scar size, and attenuate cardiac dilatation in porcine ischemic cardiomyopathy. PLoS One 2014;9:e113805
32. Houtgraaf JH, de Jong R, Kazemi K, et al. Intracoronary infusion of allogeneic mesenchymal precursor cells directly after experimental acute myocardial infarction reduces infarct size, abrogates adverse remodeling, and improves cardiac function. Circ Res 2013;113:153-66
33. Kubal C, Sheth K, Nadal-Ginard B, Galinanes M. Bone marrow cells have a potent anti-ischemic effect against myocardial cell death in humans. J Thorac Cardiovasc Surg 2006;132:1112-18
34. Nadal-Ginard B, Torella D, Ellison G. Cardiovascular regenerative medicine at the crossroads. clinical trials of cellular therapy must now be based on reliable experimental data from animals with characteristics similar to human's. Rev Esp Cardiol (Engl Ed) 2006;59:1175-89
35. Kreke M, Smith RR, Marban L, Marban E. Cardiospheres and cardiosphere-derived cells as therapeutic agents following myocardial infarction. Expert Rev Cardiovasc Ther 2012;10:1185-94
36. Hong K, Bolli R. Cardiac stem cell therapy for cardiac repair. Curr Treat Options Cardio Med 2014;16:1-19
37. Vanelli A. Isolation, characterization and differentiation potential of cardiac progenitor cells in adult pigs. PhD Thesis Università degli Studi di Milano, Milan; 2011. Available from: http://hdl.handle.net/2434/169553
38. Jezierska-Wozniak K, Mystkowska D, Tutas A, Jurkowski MK. Stem cells as therapy for cardiac disease-a review. Folia Histochem Cytobiol 2011;49:13-25
39. Sanz-Ruiz R, Arranz AV, Ibanes EG, et al. Randomized clinical trials in stem cell therapy for the heart-old and new types of cells for cardiovascular repair. In: Gholamrezanezhad A, editor. Stem cells in clinics and research. ISBN: 978-953-307-797-0 InTech, Rijeka, Croatia; 2011
40. Barile L, Chimenti I, Gaetani R, et al. Cardiac stem cells: isolation, expansion and experimental use for myocardial regeneration. Nat Clin Pract Cardiovasc Med 2007;4(Suppl 1):S9-S14
41. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003;114:763-76
42. Yarden Y, Kuang WJ, Yang-Feng T, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987;6: 3341-51
43. Edling CE, Hallberg B. c-Kit-a hematopoietic cell essential receptor tyrosine kinase. Int J Biochem Cell Biol 2007;39: 1995-8
44. Leri A. Human cardiac stem cells: the heart of a truth. Circulation 2009;120:2515-18
45. Bearzi C, Leri A, Lo Monaco F, et al. Identification of a coronary vascular progenitor cell in the human heart. Proc Natl Acad Sci USA 2009;106:15885-90
46. Gambini E, Pompilio G, Biondi A, et al. C-kit+ cardiac progenitors exhibit mesenchymal markers and preferential cardiovascular commitment. Cardiovasc Res 2011;89:362-73
47. Oh H, Bradfute SB, Gallardo TD, et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA 2003;100:12313-18
48. van de Rijn M, Heimfeld S, Spangrude GJ, Weissman IL. Mouse hematopoietic stem-cell antigen Sca-1 is a member of the Ly-6 antigen family. Proc Natl Acad Sci USA 1989;86:4634-8
49. Matsuura K, Nagai T, Nishigaki N, et al. Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. J Biol Chem 2004;279:11384-91
50. Holmes C, Stanford WL. Concise review: stem cell antigen-1: expression, function, and enigma. Stem Cell 2007;25:1339-47
51. Goodell MA, Brose K, Paradis G, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996;183: 1797-806
52. Pfister O, Mouquet F, Jain M, et al. CD31-but Not CD31+ cardiac side population cells exhibit functional cardiomyogenic differentiation. Circ Res 2005;97:52-61
53. Oh H, Chi X, Bradfute SB, et al. Cardiac muscle plasticity in adult and embryo by heart-derived progenitor cells. Ann N Y Acad Sci 2004;1015:182-9
54. Oyama T, Nagai T, Wada H, et al. Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes in vitro and in vivo. J Cell Biol 2007;176:329-41
55. Goichberg P, Chang J, Liao R, Leri A. Cardiac stem cells: biology and clinical applications. Antioxid Redox Signal 2014; 21(14):2002-17
56. Tomita Y, Matsumura K, Wakamatsu Y, et al. Cardiac neural crest cells contribute to the dormant multipotent stem cell in the mammalian heart. J Cell Biol 2005;170: 1135-46
57. Fonoudi H, Yeganeh M, Fattahi F, et al. ISL1 protein transduction promotes cardiomyocyte differentiation from human embryonic stem cells. PLoS One 2013;8: e55577
58. Barzelay A, Ben-Shoshan J, Entin-Meer M, et al. A potential role for islet-1 in post-natal angiogenesis and vasculogenesis. Thromb Haemost 2010;103:188-97
59. Barile L, Messina E, Giacomello A, Marbán E. Endogenous Cardiac Stem Cells. Prog Cardiovasc Dis 2007;50:31-48
60. Messina E, De Angelis L, Frati G, et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res 2004;95:911-21
61. Chimenti I, Smith RR, Li T-S, et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ Res 2010;106:971-80
62. Gaetani R, Rizzitelli G, Chimenti I, et al. Cardiospheres and tissue engineering for myocardial regeneration: potential for clinical application. J Cell Mol Med 2010;14:1071-7
63. Smith RR, Barile L, Cho HC, et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 2007;115:896-908
64. Di Felice V, De Luca A, Colorito ML, et al. Cardiac stem cell research: an elephant in the room? Anat Rec (Hoboken) 2009;292:449-54
65. Di Felice V, Zummo G. Stem cell populations in the heart and the role of Isl1 positive cells. Eur J Histochem 2013;57:e14
66. Koninckx R, Daniels A, Windmolders S, et al. The cardiac atrial appendage stem cell: a new and promising candidate for myocardial repair. Cardiovasc Res 2013;97: 413-23
67. Fuentes T, Kearns-Jonker M. Endogenous cardiac stem cells for the treatment of heart failure. Stem Cells Cloning 2013;6:1-12
68. Blazquez R, Sanchez-Margallo FM, de la Rosa O, et al. Immunomodulatory potential of human adipose mesenchymal stem cells derived exosomes on in vitro stimulated T cells. Front Immunol 2014;5:556
69. Maguire G, Friedman P, McCarthy D, et al. Stem cell released molecules and exosomes in tissue engineering. Procedia Eng 2013;59:270-8
70. Lai RC, Chen TS, Lim SK. Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease. Regen Med 2011;6:481-92
71. Ibrahim AG, Cheng K, Marban E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports 2014;2:606-19
72. Kami D, Watakabe K, Yamazaki-Inoue M, et al. Large-scale cell production of stem cells for clinical application using the automated cell processing machine. BMC Biotechnol 2013;13:102
73. Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007;262:509-25
74. Garcia-Castro J, Trigueros C, Madrenas J, et al. Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. J Cell Mol Med 2008;12: 2552-65
75. Anversa P, Leri A, Kajstura J. Cardiac regeneration. J Am Coll Cardiol 2006;47: 1769-76
76. Gersh BJ, Simari RD, Behfar A, et al. Cardiac cell repair therapy: a clinical perspective. Mayo Clin Proc 2009;84: 876-92
77. Huang XP, Sun Z, Miyagi Y, et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 2010;122: 2419-29
78. Grinnemo KH, Mansson A, Dellgren G, et al. Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. J Thorac Cardiovasc Surg 2004;127:1293-300
79. Timmers L, Lim SK, Hoefer IE, et al. Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Res 2011;6:206-14
80. Lauden L, Boukouaci W, Borlado LR, et al. Allogenicity of human cardiac stem/progenitor cells orchestrated by programmed death ligand 1. Circ Res 2013;112:451-64 .. Immunomodulatory properties of cardiac progenitor cells.
81. Monnet E, Chachques JC. Animal models of heart failure: what is new? Ann Thorac Surg 2005;79:1445-53
82. Suzuki Y, Yeung AC, Ikeno F. The pre-clinical animal model in the translational research of interventional cardiology. J Am Coll Cardiol Intv 2009;2: 373-83
83. Dixon JA, Spinale FG. Large animal models of heart failure. Circ Heart Fail 2009;2: 262-71
84. Suzuki Y, Yeung AC, Ikeno F. The Representative porcine model for human cardiovascular disease. J Biomed Biotechnol 2011;2011:195483
85. Li T-S, Cheng K, Malliaras K, et al. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J Am Coll Cardiol 2012;59:942-53
86. Mohsin S, Khan M, Toko H, et al. Human cardiac progenitor cells engineered with Pim-I kinase enhance myocardial repair. J Am Coll Cardiol 2012;60:1278-87
87. Oskouei BN, Lamirault G, Joseph C, et al. Increased potency of cardiac stem cells compared with bone marrow mesenchymal stem cells in cardiac repair. Stem Cells Transl Med 2012;1:116-24
88. Li Z, Lee A, Huang M, et al. Imaging survival and function of transplanted cardiac resident stem cells. J Am Coll Cardiol 2009;53:1229-40
89. Bearzi C, Rota M, Hosoda T, et al. Human cardiac stem cells. Proc Natl Acad Sci USA 2007;104:14068-73
90. Davis DR, Kizana E, Terrovitis J, et al. Isolation and expansion of functionally-competent cardiac progenitor cells directly from heart biopsies. J Mol Cell Cardiol 2010;49:312-21
91. Rota M, Padin-Iruegas ME, Misao Y, et al. Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function. Circ Res 2008;103:107-16
92. Carr CA, Stuckey DJ, Tan JJ, et al. Cardiosphere-derived cells improve function in the infarcted rat heart for at least 16 weeks-an MRI study. PLoS One 2011;6:e25669
93. van Berlo JH, Kanisicak O, Maillet M, et al. c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature 2014;509:337-41
94. Ellison GM, Vicinanza C, Smith AJ, et al. Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. Cell 2013;154:827-42
95. Linke A, Müller P, Nurzynska D, et al. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci USA 2005;102:8966-71
96. Takehara N, Tsutsumi Y, Tateishi K, et al. Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. J Am Coll Cardiol 2008;52:1858-65
97. Autologous human cardiac-derived stem cell to treat ischemic cardiomyopathy (ALCADIA). Available from: https://clinicaltrials.gov/ct2/show/NCT00981006
98. Takehara N NM, Ogata T, Nakamura T, et al. The ALCADIA (Autologous human cardiac-derived stem cell to treat ischemic cardiomyopathy) trial. late-breaking clinical trial abstracts. Circulation 2012;126: 2776-99
99. Kraitchman DL, Bulte JW. Imaging of stem cells using MRI. Basic Res Cardiol 2008;103:105-13
100. Ellison GM, Torella D, Trigueros C, et al. Use of heterologous non-matched Cardiac Stem Cells (CSCs) without immunosuppression as an effective regenerating agent in a porcine model of acute myocardial infarction. Eur Heart J 2009;30:495
101. Lee S-T, White AJ, Matsushita S, et al. Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J Am Coll Cardiol 2011;57:455-65
102. Williams AR, Hatzistergos KE, Addicott B, et al. Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation 2013;127:213-23
103. Cheng K, Li TS, Malliaras K, et al. Magnetic targeting enhances engraftment and functional benefit of iron-labeled cardiosphere-derived cells in myocardial infarction. Circ Res 2010;106:1570-81
104. Gomez-Mauricio RG, Acarregui A, Sanchez-Margallo FM, et al. A preliminary approach to the repair of myocardial infarction using adipose tissue-derived stem cells encapsulated in magnetic resonance-labelled alginate microspheres in a porcine model. Eur J Pharm Biopharm 2013;84:29-39
105. Barnett BP, Kraitchman DL, Lauzon C, et al. Radiopaque alginate microcapsules for X-ray visualization and immunoprotection of cellular therapeutics. Mol Pharm 2006;3: 531-8
106. Yang Y-J, Qian H-Y, Huang J, et al. Combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells increases benefits in infarcted swine hearts. Arterioscler Thromb Vasc Biol 2009;29:2076-82
107. Gnecchi M, He H, Melo LG, et al. Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction. Stem cells 2009;27:971-9
108. Galvez-Monton C, Prat-Vidal C, Roura S, et al. Post-infarction scar coverage using a pericardial-derived vascular adipose flap. Pre-clinical results. Int J Cardiol 2013;166: 469-74
109. Capricor. Available from: http://capricor. com/clinical-trials/allstar/
110. Ellison G, Nadal-Ginard B, Torella D. Optimizing cardiac repair and regeneration through activation of the endogenous cardiac stem cell compartment. J Cardiovasc Transl Res 2012;5:667-77